Elevance Health, Inc. $ELV Shares Sold by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP lessened its position in Elevance Health, Inc. (NYSE:ELV) by 34.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,921 shares of the company’s stock after selling 2,589 shares during the quarter. Fulcrum Asset Management LLP’s holdings in Elevance Health were worth $1,590,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ELV. Rockefeller Capital Management L.P. grew its position in Elevance Health by 3.6% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 48,555 shares of the company’s stock valued at $18,887,000 after acquiring an additional 1,676 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its position in shares of Elevance Health by 5.7% during the second quarter. Nomura Asset Management Co. Ltd. now owns 82,011 shares of the company’s stock worth $31,899,000 after purchasing an additional 4,405 shares in the last quarter. Pinnacle Wealth Planning Services Inc. lifted its position in shares of Elevance Health by 23.0% during the second quarter. Pinnacle Wealth Planning Services Inc. now owns 920 shares of the company’s stock worth $358,000 after purchasing an additional 172 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock valued at $8,890,419,000 after purchasing an additional 704,790 shares during the period. Finally, Perennial Investment Advisors LLC grew its holdings in shares of Elevance Health by 37.9% in the second quarter. Perennial Investment Advisors LLC now owns 644 shares of the company’s stock valued at $251,000 after purchasing an additional 177 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the topic of several recent research reports. Morgan Stanley cut their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Sanford C. Bernstein dropped their price target on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. JPMorgan Chase & Co. upped their price objective on Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Finally, UBS Group set a $400.00 target price on Elevance Health in a report on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Stock Down 0.3%

Shares of Elevance Health stock opened at $294.98 on Thursday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a market capitalization of $65.10 billion, a P/E ratio of 11.74, a P/E/G ratio of 1.62 and a beta of 0.51. The company has a 50 day moving average of $333.87 and a 200 day moving average of $333.89.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.